title: Pneumocandins from Zalerion arboricola. I. Discovery and isolation.
abstract: HPLC bioautography of the directed biosynthesis of Zalerion arboricola led to the discovery of pneumocandin B0 (L-688,786), a new antifungal and anti-Pneumocystis carinii lipopeptide. Isolation techniques were developed to separate this component from pneumocandin A0 (L-671,329) in fermentations of a mutant of Zalerion arboricola. A number of related compounds were also isolated, which differ from pneumocandins A0 and B0 in the hydroxylation patterns on the ornithine, homotyrosine, and proline.
authors: Merck Research Laboratories, Rahway, N.J. 07065-0900.
authors: R E
authors: RE
authors: Schwartz
authors: D F
authors: DF
authors: Sesin
authors: H
authors: H
authors: Joshua
authors: K E
authors: KE
authors: Wilson
authors: A J
authors: AJ
authors: Kempf
authors: K A
authors: KA
authors: Goklen
authors: D
authors: D
authors: Kuehner
authors: P
authors: P
authors: Gailliot
authors: C
authors: C
authors: Gleason
authors: R
authors: R
authors: White
mesh_terms: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D001711:Biotransformation; D002176:Candida albicans / Q000187:drug effects; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D054714:Echinocandins; D008826:Microbial Sensitivity Tests; D008828:Microbiological Techniques; D003904:Mitosporic Fungi / Q000737:chemistry* / Q000378:metabolism; D010455:Peptides; D010456:Peptides, Cyclic / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D011010:Pneumocystis / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; C058995:pneumocandin A(0); C079465:pneumocandin B(0); C079464:pneumocandin C(0)